Intravitreal Injection Anesthesia - Comparison of Different Topical Agents

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with neovascular age-related macular degeneration (AMD) scheduled to receive intravitreal (IVT) Ranibizumab injection will be randomized to receive one of three topical anesthetics: (1) tetracaine drop (gtt) + lidocaine pledget to the injection site for 10 seconds (2) tetracaine gtt alone and (3) cocaine gtt alone. A questionnaire will be conducted immediately after and 15 minutes after the injection, to assess for pain.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lawson Health Research Institute
• Treatments: Anesthetics; Cocaine; Lidocaine; Tetracaine

Criteria

Inclusion Criteria:

1. Age greater than 50

2. Scheduled to receive Ranibizumab for neovascular AMD

Exclusion Criteria:

1. History of pars plana vitrectomy

2. Any major surgery within the prior 28 days, or one planned within next 6 months

3. History of thromboembolic event

4. Previous known allergic response to topical anesthetic(s) (lidocaine, tetracaine, cocaine)